Merrimack Pharmaceuticals Inc. (MACK) Announces Encouraging Clinical Data From Expanded Phase 1 Study Of MM-302 For The Treatment Of Advanced HER2-Positive Breast Cancer
12/13/2013 9:28:45 AM
CAMBRIDGE, Mass., Dec. 13, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced Phase 1 clinical trial results for MM-302, a novel HER2-targeted liposomal doxorubicin for the treatment of advanced HER2-positive breast cancer. Primary objectives for the trial are to assess the safety of MM-302 as a monotherapy and in combination with trastuzumab, as well as to determine the Phase 2 dose for MM-302. Data were presented at the 2013 San Antonio Breast Cancer Symposium, Dec. 10-14, 2013 in San Antonio, Texas.
Help employers find you! Check out all the jobs and post your resume.
comments powered by